INDEPENDENT THINKING. WHOLE-FOOD LIVING.NO ANIMALS / NO OIL
THENANODIET
← THE STUDY LIBRARY

Narrative review / 2024

A review highlights that therapies achieving robust and sustained LDL-C reduction can reduce atherosclerotic cardiovascular disease risk.

This review examines the role of early, intensive, and sustained LDL-C lowering for primary and secondary prevention of atherosclerotic cardiovascular disease (ASCVD). Cumulative exposure to LDL-C drives ASCVD risk, and no established LDL-C threshold exists below which clinical benefits cease or safety concerns arise. Interventions discussed include lifestyle modifications, statins, ezetimibe, bempedoic acid, PCSK9 inhibitors, siRNA therapy, evinacumab, and emerging agents.

Study type
Narrative review
Who was studied
Patients indicated for primary or secondary ASCVD prevention
What was measured
Atherosclerotic cardiovascular disease (ASCVD) risk reduction and LDL-C lowering

THE PAPER

The importance of LDL-C lowering in atherosclerotic cardiovascular disease prevention: Lower for longer is better.

Mhaimeed O, Burney ZA, Schott SL, Kohli P, Marvel FA, Martin SS. Am J Prev Cardiol, 2024.

PubMed 38576462 ↗DOI 10.1016/j.ajpc.2024.100649 ↗

Heart & arteriesDiabetes & blood sugar

This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.